174 related articles for article (PubMed ID: 16837154)
1. [Blood and respiratory diffusion of antibiotics. A critical analysis of predictive parameters for clinical effectiveness].
Fantin B
Med Mal Infect; 2006; 36(11-12):599-613. PubMed ID: 16837154
[TBL] [Abstract][Full Text] [Related]
2. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
5. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
Reed MD
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
[TBL] [Abstract][Full Text] [Related]
6. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.
Drusano GL; Craig WA
J Chemother; 1997 May; 9 Suppl 3():38-44. PubMed ID: 9248979
[TBL] [Abstract][Full Text] [Related]
7. How can we predict bacterial eradication?
Jacobs MR
Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
[TBL] [Abstract][Full Text] [Related]
8. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
9. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Appelbaum PC
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
12. Does the dose matter?
Craig WA
Clin Infect Dis; 2001 Sep; 33 Suppl 3():S233-7. PubMed ID: 11524724
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries.
Lee MY; Ko KS; Oh WS; Park S; Lee JY; Baek JY; Suh JY; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics: relation to antimicrobial resistance.
Rybak MJ
Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
[TBL] [Abstract][Full Text] [Related]
17. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Liu P; Rand KH; Obermann B; Derendorf H
Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
[TBL] [Abstract][Full Text] [Related]
19. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Conte JE; Golden JA; Kelly MG; Zurlinden E
Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
[TBL] [Abstract][Full Text] [Related]
20. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
